Amgen Inc.

Huyabio International, LLC

Medarex Inc.

Cephalon, Inc.

Huya Bioscience International, LLC

E. R. Squibb Sons, Inc.

Huya Biosciences International LLC

Gary Elliott

Suzanne J Romano

Haichun Huang

Francis Hall Martin

Alison Witte

Brian C Varnum

Robert Goodenow

Xueming Qian

Chris Vezina

Mireille Gillings

Shuqian Jing

Eugene Medlock

Richard Yeh

Daniel Freeman

Qi Chao

Andrew A Welcher

Robert Radinsky

Scott Michael Silbiger

Hayley Reece

Lorenzo Leoni

Jilin Sun

Waldemar Radziszewski

Jay Mason

Joseph Edward Gordon Benson

Sarah Collins

Curtis Tyree

Hung Q Nquyen

Hung Q Nguyen

Frank Martin

Kenneth H Jung

Mimi K Phillips

Scott Michael Sibiger

James R Paterniti, Jr

Ernst Freund

Jorg Lill

Oliver SCHLÖRKE

Dario Menia

James R Paterniti

Andreas Kyas

Lars Rogall

Oliver Schlorke

Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.

Sulcardine administration for treatment of acute atrial fibrillation

Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Sulcardine salts

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Therapeutic human anti-IL-1R1 monoclonal antibody

The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.

Methods of selecting epidermal growth factor receptor (EGFr) binding agents

A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with rapid intravenous or even short-term infusion administration of the active agent.

Slow infusion of sulcardine and its salts

Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 &#x3bc;M to about 20 &#x3bc;M.

Treatment of atrial fibrillation

Methods of selecting epidermal growth factor receptor (EGFR) binding agents

The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.

IL-17 receptor like molecules and uses thereof

Growing community of inventors

Thousand Oaks, CA, United States of America

Gary Elliott